Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · Real-Time Price · USD

7.85

-0.13 (-1.63%)

At close: May 01, 2025, 3:59 PM

7.84

-0.13%

After-hours: May 01, 2025, 05:15 PM EDT

-1.63% (1D)

Bid	7.8
Market Cap	520.01M
Revenue (ttm)	n/a
Net Income (ttm)	-46.36M
EPS (ttm)	-0.82
PE Ratio (ttm)	-9.57
Forward PE	-5.72
Analyst	Hold

Ask	7.93
Volume	4,958,979
Avg. Volume (20D)	1,747,157
Open	7.83
Previous Close	7.98
Day's Range	7.77 - 7.95
52-Week Range	0.83 - 8.20
Beta	1.02

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 9, 2012

Employees 34

Stock Exchange NASDAQ

Ticker Symbol RGLS

Website https://www.regulusrx.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for RGLS stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 1.91% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

+136.8%

Regulus Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

1 month ago

+16.28%

Regulus Therapeutics shares are trading higher after the company announced topline results from the phase 1b MAD study of Farabursen for autosomal dominant polycystic kidney disease.

News

1 day ago · benzinga.com

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.

1 day ago · benzinga.com

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

1 day ago · businesswire.com

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareh...

1 day ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to l...

1 day ago · reuters.com

Novartis to buy Regulus Therapeutics for up to $1.7 billion

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

6 days ago · zacks.com

Should You Buy Regulus (RGLS) After Golden Cross?

Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above...

1 month ago · benzinga.com

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD) o...